Holen Sie sich die Stockscreener-App
25.74
0.12%
0.03
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$25.71
Offen:
$25.85
24-Stunden-Volumen:
22.62M
Relative Volume:
0.34
Marktkapitalisierung:
$146.35B
Einnahmen:
$62.79B
Nettoeinkommen (Verlust:
$9.84B
KGV:
15.00
EPS:
1.7156
Netto-Cashflow:
$10.38B
1W Leistung:
+2.80%
1M Leistung:
+5.06%
6M Leistung:
+11.04%
1J Leistung:
-0.35%
1-Tages-Spanne:
$25.66
$25.86
1-Wochen-Bereich:
$25.05
$25.97
52-Wochen-Spanne:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.74 | 146.18B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,075.47 | 988.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.92 | 500.07B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.70 | 402.36B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
130.40 | 250.29B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
104.83 | 259.69B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
With 66% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns - Yahoo Finance
Is Pfizer Stock Underperforming the Dow? - Barchart.com
Guggenheim Lifts PT on Pfizer Inc. (PFE) to $35 From $33, Keeps a Buy Rating - MSN
Atopic Dermatitis Drugs Market to Reach $29.43 Billion by 2032, Driven by Rising Disease Prevalence & Strong Therapeutic Innovation | SNS Insider - GlobeNewswire Inc.
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet? - Yahoo Finance
Quarterly Risk: Will Pfizer Inc. stock beat EPS estimatesJuly 2025 Rallies & Low Risk Growth Stock Ideas - moha.gov.vn
How resilient is Pfizer Inc. stock in market downturnsJuly 2025 Sector Moves & Weekly Setup with ROI Potential - BỘ NỘI VỤ
U.S. Meibomian Gland Dysfunction Market to Get an Explosive - openPR.com
Does the Recent 3.3% Rally Change the Picture for Pfizer’s True Value? - simplywall.st
Valneva's Lyme Vaccine Booster Results Show PromiseValneva (NASDAQ:VALN), Pfizer (NYSE:PFE) - Benzinga
Is Pfizer Stock A Buy After It Clinches The $10 Billion Takeover Of Metsera? - Investor's Business Daily
AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights - Yahoo Finance
PFIZER INC : Berenberg reaffirms its Neutral rating - MarketScreener
Did Pfizer Just Say "Checkmate" to Novo Nordisk? - Yahoo Finance
Pfizer’s CFO on building a post-Covid future and how it won the fight for Metsera - Sherwood News
Is This Pfizer (NYSE:PFE) Coverage Worth Reading Today? - Kalkine Media
Pfizer (PFE) Sees Significant Options Activity in Latest Trading Session - GuruFocus
Jim Cramer on Pfizer: “I Think It Can Be Near a Breakout” - Insider Monkey
Is This the Best Value Stock to Buy While Markets Are Volatile? - Finviz
Vyndaqel Market Set to Significantly Grow from 2025 to 2032 | Pfizer Inc - openPR.com
Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors? - Yahoo Finance
Should FDA Approval of PADCEV Plus Keytruda Shift Pfizer's (PFE) Oncology Innovation Outlook? - simplywall.st
Which Is A Better Pick: Johnson & Johnson or Pfizer Stock? - Trefis
Guggenheim Raises Price Target for Pfizer (PFE) to $35 | PFE Sto - GuruFocus
Guggenheim Adjusts Price Target on Pfizer to $35 From $33, Maintains Buy Rating - MarketScreener
14 Stocks Jim Cramer Recently Shed Light On - Insider Monkey
MCC STEM students and employees visit Pfizer - Lowell Sun
A Look at Pfizer's Valuation Following FDA Approval of PADCEV Combination Therapy for Bladder Cancer - simplywall.st
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon - Finviz
Pfizer Secures a Major Regulatory Win—How Will Its U.S. Drug Pricing Deal Shape 2026? - Smartkarma
Does Pfizer’s AI-Powered R&D Signal a New Opportunity for 2025? - Yahoo Finance
Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know - The Globe and Mail
Pfizer Inc. (PFE) Completes Significant Public Offering of Notes - GuruFocus
Pfizer completes $6 billion public notes offering across multiple maturities - Investing.com
Pfizer completes $6 billion public notes offering across multiple maturities By Investing.com - Investing.com India
Pfizer Sells $6 Billion of Notes - MarketScreener
Pfizer Completes $5 Billion Public Offering - TipRanks
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
[8-K] PFIZER INC Reports Material Event | PFE SEC FilingForm 8-K - Stock Titan
Why Are Shares of Pfizer Up Today? - Benzinga
Pfizer, Astellas Say FDA Approves Padcev-Keytruda Combo in Bladder Cancer - MarketScreener
Pfizer (PFE) Gains FDA Approval for New Bladder Cancer Treatment - GuruFocus
mRNA flu shot shows better results than traditional vaccine in trial - upi.com
Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025 - ts2.tech
Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant StrainsPfizer (NYSE:PFE) - Benzinga
New Trial Shows Pfizer’s mRNA Flu Shot Beats Traditional Flu Vaccine - Citizen Tribune
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
Medical Morphine Market Deep Research Report with Forecast - openPR.com
Necrotizing Fasciitis Market to Witness Remarkable Growth With - openPR.com
Amazon and Pfizer plunder $22bn on final approach to Thanksgiving - GlobalCapital
Pfizer (PFE) Agrees to $41.5 Million Settlement Over Drug Allega - GuruFocus
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.31%
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):